Komori
Mochida Pharmaceutical (4534) · InitiativeRestated

Preparing to adopt the new revenue recognition and fair value measurement standards

First written in FY2021. 2 of 4 entries say "Restated". Latest entry: FY2022-Q3.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021AchievedFY2022-Q1RestatedFY2022-Q2 – FY2022-Q32021: 320212022: 12022
Same theme, other companies
Simultaneous application of the Revenue Recognition and Fair Value Measurement Accounting StandardsA theme 199 companies write about · 7 as a headwind · 2 as a tailwind

126 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3RestatedAnnual report

    「The 'Accounting Standard for Revenue Recognition' (ASBJ Statement No. 29, 31 March 2020; hereinafter, the 'Revenue Recognition Standard') and related standards have been applied from the beginning of the first quarter of the current fiscal year. Revenue is recognised at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The company continues to apply the Revenue Recognition Standard and the Fair Value Measurement Standard from the beginning of the current fiscal year. The impact of the Revenue Recognition Standard on profit and loss was immaterial, while the Fair Value Measurement Standard had no impact, according to the disclosure.
  2. FY2022-Q2RestatedAnnual report

    「The 'Accounting Standard for Revenue Recognition' (ASBJ Statement No. 29, 31 March 2020; hereinafter, the 'Revenue Recognition Standard') and related standards have been applied from the beginning of the first quarter of the current fiscal year. Revenue is recognised at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer.」

    The company continues to apply the Revenue Recognition Standard and the Fair Value Measurement Standard from the beginning of the current fiscal year. The impact of the Revenue Recognition Standard on profit and loss for the six months ended the second quarter of the current fiscal year was immaterial, while the Fair Value Measurement Standard had no impact, according to the disclosure.
  3. FY2022-Q1AchievedAnnual report

    「The 'Accounting Standard for Revenue Recognition' (ASBJ Statement No. 29, 31 March 2020; hereinafter, the 'Revenue Recognition Standard') and related standards have been applied from the beginning of the first quarter of the current fiscal year. Revenue is recognised at the amount expected to be received in exchange for the promised goods or services when control of those goods or services is transferred to the customer. The 'Accounting Standard for Fair Value Measurement' (ASBJ Statement No. 30, 4 July 2019; hereinafter, the 'Fair Value Measurement Standard') and related standards have also been applied from the beginning of the first quarter of the current fiscal year, and the new accounting policies prescribed by the Fair Value Measurement Standard and related standards have been applied prospectively.」

    The Revenue Recognition Standard and the Fair Value Measurement Standard were applied from the beginning of the first quarter of the fiscal year ending March 2022, which was the beginning of the fiscal year. The impact of the Revenue Recognition Standard on profit and loss was immaterial, while the Fair Value Measurement Standard had no impact on the quarterly consolidated financial statements, according to the disclosure.
  4. FY2021First statedAnnual report

    「The 'Accounting Standard for Revenue Recognition' and the 'Implementation Guidance on the Accounting Standard for Revenue Recognition' are scheduled to be applied from the beginning of the fiscal year ending March 2022. The impact of applying these accounting standards and related guidance is immaterial.」

    The company plans to apply the new accounting standards on revenue recognition and fair value measurement from the beginning of the fiscal year ending March 2022, with the impact expected to be immaterial.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Preparing to adopt the new revenue recognition and fair value measurement standards | Mochida Pharmaceutical Co.,Ltd. (4534) | Komori